keyword
MENU ▼
Read by QxMD icon Read
search

Stage I seminoma

keyword
https://www.readbyqxmd.com/read/29306641/testicular-seminoma-scattered-radiation-dose-to-the-contralateral-testis-in-the-modern-era
#1
Hester Lieng, Peter Chung, Tony Lam, Padraig Warde, Tim Craig
PURPOSE: Limited data exist on testicular dose measurements using modern radiation treatment techniques and volumes for testicular seminoma. The aim of this study was to report the testicular dose using in vivo measurements in men with testicular seminoma receiving abdominopelvic radiation therapy (APRT) and a modified dog-leg field with and without gonadal shielding. METHODS AND MATERIALS: Men with histologically confirmed testicular seminoma, either newly diagnosed stage II disease or isolated retroperitoneal relapse on surveillance for stage I disease, treated with APRT had testicular dose measurements recorded using MOSFET dosimeters...
January 3, 2018: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29301509/assessment-of-pirna-biogenesis-and-function-in-testicular-germ-cell-tumors-and-their-precursor-germ-cell-neoplasia-in-situ
#2
Ildar V Gainetdinov, Yulia V Skvortsova, Sofia A Kondratieva, Alexey Klimov, Alexey A Tryakin, Tatyana L Azhikina
BACKGROUND: Aberrant overexpression of PIWI/piRNA pathway proteins is shown for many types of tumors. Interestingly, these proteins are downregulated in testicular germ cell tumors (TGCTs) compared to normal testis tissues. Here, we used germline and TGCT markers to assess the piRNA biogenesis and function in TGCTs and their precursor germ cell neoplasia in situ (GCNIS). METHODS: We used small RNA deep sequencing, qRT-PCR, and mining public RNAseq/small RNA-seq datasets to examine PIWI/piRNA gene expression and piRNA biogenesis at four stages of TGCT development: (i) germ cells in healthy testis tissues, (ii) germ cells in testis tissues adjacent to TGCTs, (iii) GCNIS cells and (iv) TGCT cells...
January 4, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29279100/long-term-toxicity-of-the-treatment-for-germ-cell-cancer-a-review
#3
REVIEW
P Maroto, G Anguera, C Martin
Testicular germ-cell cancer (GCC) is a curable disease. Stage I patients are mostly cured by surgery alone. For those with good prognosis advanced disease, radiotherapy in some patients with stage II Seminoma and chemotherapy for all other patients, are responsible for 95% of long-term survivors. Unfortunately, despite this high level of curability, overall survival has been reported lower for those patients receiving either radiotherapy or chemotherapy versus patients treated by surgery alone. Long-term survivors face a higher incidence of second neoplasms, and a higher risk of cardiovascular disease and metabolic syndrome than expected...
January 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29218213/two-cases-of-somatic-type-malignancy-as-a-very-late-relapse-of-testicular-cancer-successfully-managed-by-surgical-resection
#4
Satoshi Washino, Tsuzumi Konishi, Kimitoshi Saito, Masashi Ohshima, Yuhki Nakamura, Tomoaki Miyagawa
A late-relapse germ cell tumor might contain malignant non-germ cell tumors, known as 'somatic-type malignancy (SM)'. The development of a secondary SM is rare, and this phenomenon remains poorly understood. Case 1 developed lung metastasis 13 years after chemotherapy followed by retroperitoneal lymph node dissection for stage IIA non-seminoma. The tumor increased in size after chemotherapy. The patient underwent a pneumonectomy. Pathology revealed an adenocarcinoma with immature teratoma. The patient has experienced no relapse for 9 years...
November 2017: Journal of Surgical Case Reports
https://www.readbyqxmd.com/read/29199728/testicular-seminoma-are-clinical-features-and-treatment-outcomes-any-different-in-india
#5
M Anjanappa, A Kumar, S Mathews, J Joseph, K M Jagathnathkrishna, F V James
AIM: This study aims to identify clinical features, treatment outcomes, and prognostic factors for relapse and survival in patients with testicular seminoma. MATERIALS AND METHODS: Retrospective analysis of all patients with pure seminoma treated at our center during over a decade (January 2005-December 2014) was carried out. Patient demographics, tumor characteristics, and treatment details and pattern of recurrence were recorded in a structured format, and disease-free survival and overall survival were calculated...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29180926/radiotherapy-in-testicular-germ-cell-tumours-a-literature-review
#6
REVIEW
Joanna Jonska-Gmyrek, Piotr Peczkowski, Wojciech Michalski, Grazyna Poniatowska, Agnieszka Zolciak-Siwinska, Beata Kotowicz, Pawel Wiechno, Magdalena Golawska, Maria Kowalska, Tomasz Demkow
Testicular germ cell tumours (GCT) represent about 1-2% of malignant in men. The essential therapeutic option for early-stage GCT is radical orchiectomy (RO), except in situations that require immediate chemotherapy in patients with a massive dissemination and unequivocally elevated levels of tumour markers. Postoperative radiotherapy (PORT) in patients with testicular seminoma in Clinical Stage I (CS I) is one of the treatment options next to active surveillance (AS) and chemotherapy (CHTH). Regardless of the procedure, five-year survival in this group of patients ranges between 97% and 100%...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/29135122/the-role-of-the-multidisciplinary-team-in-the-decision-making-process-in-stage-one-testicular-cancer-retrospective-cohort-analysis
#7
Tomislav Omrcen, Andrija Katic, Eduard Vrdoljak
PURPOSE: To analyze the role of a multidisciplinary team (MDT) in the decision-making process in clinical stage one (CS I) testicular cancer (TC). METHODS: We retrospectively evaluated data on 115 consecutive patients with CS I TC (excluding stage IS) who were referred to the Department of Oncology, University Hospital of Split, Croatia, from 2003 to 2012. Fifty-six patients (48.7%) were referred between 2003 and 2007, before the introduction of the MDT and 59 patients (51...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29100813/testicular-tumour-size-and-rete-testis-invasion-as-prognostic-factors-for-the-risk-of-relapse-of-clinical-stage-i-seminoma-testis-patients-under-surveillance-a-systematic-review-by-the-testicular-cancer-guidelines-panel
#8
REVIEW
Joost L Boormans, Javier Mayor de Castro, Lorenzo Marconi, Yuhong Yuan, M Pilar Laguna Pes, Carsten Bokemeyer, Nicola Nicolai, Ferran Algaba, Jan Oldenburg, Peter Albers
CONTEXT: Patients with clinical stage I (CS I) seminoma testis with large primary tumours and/or rete testis invasion (RTI) might have an increased risk of relapse. In recent years, these risk factors have frequently been employed to decide on adjuvant treatment. OBJECTIVE: To systematically review the literature on tumour size and RTI as risk factors for relapse in CS I seminoma testis patients under surveillance. EVIDENCE ACQUISITION: Relevant databases including Medline, Embase, and the Cochrane Library were searched up to November 2016...
October 31, 2017: European Urology
https://www.readbyqxmd.com/read/29045540/phase-ii-trial-of-pembrolizumab-in-patients-with-platinum-refractory-germ-cell-tumors-a-hoosier-cancer-research-network-study-gu14-206
#9
N Adra, L H Einhorn, S K Althouse, N R Ammakkanavar, D Musapatika, C Albany, D Vaughn, N H Hanna
Background: Despite remarkable results with salvage standard-dose or high-dose chemotherapy about 15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT. Patients and Methods: Single arm phase 2 trial investigating pembrolizumab 200mg IV Q3weeks until disease progression in patients with relapsed GCT and no curable options...
October 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29032579/incidentally-detected-testicular-lesions-10-mm-in-diameter-can-orchidectomy-be-avoided
#10
Glenda Scandura, Clare Verrill, Andrew Protheroe, Johnson Joseph, Wendy Ansell, Anju Sahdev, Jonathan Shamash, Daniel M Berney
OBJECTIVE: To investigate the pathology of excised testicular lesions <10 mm in size. PATIENTS AND METHODS: The pathological reports of 2 681 patients with testicular lesions from Barts Health NHS Trust and Oxford University Hospitals NHS Foundation Trust were reviewed as part of a service evaluation audit from January 2003 to May 2016. Cases in which the lesion had a maximum diameter of <10 mm were selected. Clinical features were also accessed, where available, to examine patient demographics, prediagnostic levels of serum markers, ultrasonographic findings and clinical details...
October 15, 2017: BJU International
https://www.readbyqxmd.com/read/29026972/retroperitoneal-lymph-node-dissection-for-testicular-seminomas-population-based-practice-and-survival-outcomes
#11
Hiten D Patel, Gregory A Joice, Zeyad R Schwen, Alice Semerjian, Ridwan Alam, Arnav Srivastava, Mohamad E Allaf, Phillip M Pierorazio
PURPOSE: While retroperitoneal lymph node dissection (RPLND) is traditionally reserved for nonseminomatous germ cell tumors, recent efforts to reduce long-term toxicities of radiation and chemotherapy have turned attention to its application for testicular seminomas. Currently, RPLND is reserved for the post-chemotherapy for stage II testicular seminomas; we aimed to describe current utilization of RPNLD for testicular seminomas by stage and implications for survival. METHODS: A national sample of men diagnosed with stage IA/IB/IS/IIA/IIB/IIC testicular seminoma (1988-2013) was evaluated from SEER Program registries...
October 12, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28949950/new-treatments-for-stage-i-testicular-cancer
#12
Lucia Nappi, Craig R Nichols, Christian K Kollmannsberger
Clinical stage I represents the most frequent presentation of both seminoma and nonseminoma testicular cancer. Despite a survival rate of close to 100%, the management of patients with this disease stage is controversial. The recurrence rate is 10% to 20% for patients with stage I seminoma and 15% to 50% for those with stage I nonseminoma. A highly sensitive and specific biomarker of relapse that is applicable to both seminoma and nonseminoma, and able to drive a definitive risk-adapted management of the patients, still is not available...
August 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28949942/testicular-seminoma-oncologic-rationale-and-role-of-surgery-in-treatment
#13
Nitin K Yerram, Hans C Arora, Abhinav Khanna, Kyle Ericson, Andrew Y Sun, Paurush Babbar, Naveen Nandanan, Andrew J Stephenson
Seminomas account for approximately 50% of all cases of testicular cancer. Testicular cancer is a highly curable disease that can be broadly classified as either seminomatous or nonseminomatous; the management and treatment of the 2 forms vary widely. Although surgery plays a large role in the management of nonseminoma, its role in the management of seminoma is much more limited. Most clinicians in the United States choose orchiectomy followed by surveillance for patients with stage I seminomatous disease, and chemotherapy or radiation-followed by surgery for the management of residual masses-for patients with disease that is stage II and higher...
September 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28935185/impact-of-hospital-case-volume-on-testicular-cancer-outcomes-and-practice-patterns
#14
Solomon L Woldu, Justin T Matulay, Timothy N Clinton, Nirmish Singla, Laura-Maria Krabbe, Ryan C Hutchinson, Arthur Sagalowsky, Yair Lotan, Vitaly Margulis, Aditya Bagrodia
BACKGROUND: Given the rarity of testicular germ cell tumors (TGCTs) and the complex aspects of management, we evaluate the effect of hospital TGCT case volume on overall survival outcomes and practice patterns. MATERIALS AND METHODS: The National Cancer Database was queried for patients diagnosed with seminoma or nonseminomatous germ cell tumor (NSGCT). Hospitals were classified by case volume as high (99th percentile, ≥26.1 cases annually), high-intermediate (95-99th percentile, 14...
September 18, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28872098/is-a-diagnostic-video-assisted-thoracoscopic-thymectomy-an-acceptable-first-line-approach-to-the-suspicious-anterior-mediastinal-mass
#15
Ricky Vaja, Vijay Joshi, Alan G Dawson, David A Waller
INTRODUCTION: The incidental early-stage thymic mass presents a diagnostic challenge. Video-assisted thoracoscopic (VAT) thymectomy is an attractive but potentially morbid solution. The aim was to show it can be safely applied as a first-line modality in those with undiagnosed thymic enlargement with acceptable long-term results. METHODS: A total of 45 patients were identified (24 male, median age 52 interquartile range [IQR]: 41-66 years) in a 14-year experience who had CT evidence of an enlarged, possibly malignant thymic mass, but no tissue diagnosis before undertaking VAT thymectomy...
October 2017: Journal of Minimal Access Surgery
https://www.readbyqxmd.com/read/28866371/no-longer-any-role-for-routine-follow-up-chest-x-rays-in-men-with-stage-i-germ-cell-cancer
#16
MULTICENTER STUDY
H De La Pena, A Sharma, C Glicksman, J Joseph, M Subesinghe, Z Traill, C Verrill, M Sullivan, J Redgwell, E Bataillard, E Pintus, N Dallas, A Gogbashian, M Tuthill, A Protheroe, M Hall
Following radical orchidectomy for testicular cancer, most patients undergo protocolled surveillance to detect tumour recurrences rather than receive adjuvant chemotherapy. Current United Kingdom national and most international guidelines recommend that patients require a chest x-ray (CXR) and serum tumour markers at each follow-up visit as well as regular CT scans; there is however, variation among cancer centres with follow-up protocols. Seminomas often do not cause tumour marker elevation; therefore, CT scans are the main diagnostic tool for detecting relapse...
October 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28852960/long-term-cardiovascular-complications-in-stage-i-seminoma-patients
#17
A Terbuch, F Posch, L M Annerer, T Bauernhofer, M Pichler, J Szkandera, G C Hutterer, K Pummer, R Partl, K S Kapp, H Stöger, A Gerger, M Stotz
PURPOSE: The cure rate of stage I seminoma patients is close to 100% and so the recent focus of clinical research has shifted onto the prevention of treatment-related complications. We assessed long-term cardiovascular complications and identified risk factors for cardiovascular events (CVEs) in stage I seminoma patients. METHODS: This retrospective cohort study included 406 consecutive stage I seminoma patients. Primary endpoint was CVE rate. RESULTS: During a median follow-up of 8...
November 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28817915/re-outcome-of-men-with-relapse-after-adjuvant-carboplatin-for-clinical-stage-i-seminoma
#18
Jerome P Richie
No abstract text is available yet for this article.
September 2017: Journal of Urology
https://www.readbyqxmd.com/read/28816282/-long-term-follow-up-experience-of-comprehensive-treatment-of-testicular-mixed-germ-cell-tumors
#19
J F Ye, B Wang, L L Ma, L Zhao, G L Wang, K Hong
OBJECTIVE: Testicular mixed germ cell tumor is mixed with embryonal carcinoma, choriocarcinoma, yolk sac tumor, teratoma, seminoma and other two or more components of the testicular tumor, the clinical is relatively rare and high degree of malignancy, this article will summarize its clinical features and optimize its treatment. METHODS: A retrospective analysis of the clinical data of 22 patients with testicular tumor mixed germ cell in Peking University Third Hospital from May 1994 to November 2016 was conducted using a combination of statistical analysis and discussion of the relevant literature...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28712791/radiotherapy-for-stage-i-and-ii-testicular-seminomas-secondary-malignancies-and-survival
#20
Hiten D Patel, Arnav Srivastava, Ridwan Alam, Gregory A Joice, Zeyad R Schwen, Alice Semerjian, Mohamad E Allaf, Phillip M Pierorazio
INTRODUCTION: Testicular seminoma affects relatively young men with excellent survival outcomes. There has been increasing concern that radiotherapy (RT) leads to secondary malignant neoplasms (SMNs) and subsequent mortality. We evaluated the effect of RT on incidence of SMNs and quantified cancer-related mortality and other causes of death for patients with stage I and II testicular seminoma. MATERIAL AND METHODS: A national sample of men (1988-2013) diagnosed with stage IA/IB/IS/IIA/IIB/IIC testicular seminomas from Surveillance, Epidemiology, and End Results were evaluated...
July 13, 2017: Urologic Oncology
keyword
keyword
110966
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"